--- a
+++ b/clusters/3009knumclusters/clust_53.txt
@@ -0,0 +1,460 @@
+Uncontrolled blood pressure despite medical treatment
+Participants may not have any evidence of ongoing inadequately controlled hypertension (defined as a systolic blood pressure [BP] of > 140 mmHg or a diastolic BP of > 90 mmHg); patients with hypertension may not be on more than three antihypertensive medications for management of their blood pressure (medications that combine two anti-hypertensives into one are considered as two medications); it is strongly recommended that patients who require three antihypertensive medications for baseline management of pre-existing hypertension be actively followed by a cardiologist or blood pressure specialist for management of BP while on protocol
+Current uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management) as well as prior history of hypertensive crisis or hypertensive encephalopathy.
+Adequately controlled blood pressure (BP) < 140 mmHg (systolic) and < 90 mmHg (diastolic) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of 3 antihypertensive medications; a cardiologist or blood pressure specialist must evaluate patients who are on 3 antihypertensive medications within 4 weeks of enrollment
+Patients with uncontrolled high blood pressure (i.e., systolic/diastolic blood pressure > 99th percentile) are not eligible
+Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria)
+Patients must not have inadequately controlled hypertension; patients must have documented blood pressures of systolic blood pressure (SBP) < 150 and diastolic blood pressure (DBP) < 90 within 14 days of starting randomization; blood pressure medications (any number) are permitted
+Patients with uncontrolled hypertension are ineligible; uncontrolled hypertension is defined as follows:\r\n* Patients aged =< 17 years: greater than 95th percentile systolic and diastolic blood pressure based on age and height which is not controlled by one anti-hypertensive medication\r\n* Patients aged > 17 years: systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg that is not controlled by one anti-hypertensive medication
+Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP 90 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria
+Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1
+Uncontrolled hypertension despite appropriate medical therapy (blood pressure [BP] greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening visit); Note: patients may be rescreened after adjustment of antihypertensive medications
+Blood pressure that is not controlled despite > 2 oral agents (systolic blood pressure [SBP] > 160 and diastolic blood pressure [DBP] > 90 documented during the screening period with no subsequent blood pressure readings > 160/100)
+Persistent uncontrolled hypertension (systolic >160 mmHg/ diastolic >100 mmHg Exclusion Criteria Part D
+Patients’ baseline blood pressure must be adequately controlled with or without antihypertensive medications prior to enrollment (systolic < 140 mmHg, diastolic < 90 mmHg)
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg); Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP / DBP ratio must be < 140/90 mmHg in order for a subject to be eligible for the study
+Inadequately controlled hypertension (defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg) despite antihypertensive medication
+Inadequately controlled hypertension (defined as systolic blood pressure ? 200 mmHg and/or diastolic blood pressure ? 120 mmHg) on more than one occasion in the month before planned day of infusion
+Poorly-controlled hypertension as defined blood pressure (BP) > 150/100 mmHg, or systolic blood pressure (SBP) > 180 mmHg when diastolic blood pressure (DBP) < 90 mmHg, on at least 2 repeated determinations on separate days within 3 months prior to study enrollment
+Systolic blood pressure > 160 mmHg or < 90 mmHg
+Patients who are currently receiving more than one anti-hypertensive medication (grade 3) or whose blood pressure is not controlled are not eligible for study enrollment
+History of uncontrolled hypertension (Blood pressure ? _140/90 mmHg and change in antihypertensive medication within 7 days prior to randomization) that is not well managed by medication and the risk of which may be precipitated by a VEGF inhibitor therapy.
+Blood pressure >140/80
+Uncontrolled high blood pressure defined as systolic blood pressure (BP) greater than or equal to 150 mmHg or diastolic BP greater than or equal to 100 mmHg with or without anti-hypertensive medication. Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.
+Adequately controlled blood pressure
+Patients with uncontrolled or poorly-controlled hypertension (> 160 mmHg systolic or > 100 mmHg diastolic for > 4 weeks) despite standard medical management
+Uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg.
+Uncontrolled or poorly controlled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 100 mmHg); Note: an isolated reading that is not sustained will be permitted
+Patients with uncontrolled hypertension as defined as systolic blood pressure of > 140 mmHg or diastolic blood pressure of > 90 mmHg documented on 2 consecutive measurements taken at least 24 hours apart are not eligible; Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values will be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean systolic blood pressure (SBP)/diastolic blood pressure (DBP) ratio must be < 140/90 mmHg in order for a subject to be eligible for the study
+Uncontrolled hypertension (diastolic blood pressure > 100 mmHg; systolic blood pressure > 150 mmHg)
+Participants with a history of hypertension must be adequately controlled with antihypertensive medication and blood pressure (BP) must be less than 140/90 mmHg prior to initiation of ziv-aflibercept
+Patients’ baseline blood pressure must be adequately controlled with or without antihypertensive medications prior to enrollment (systolic =< 140 mmHg, diastolic =< 90 mmHg)
+Uncontrolled hypertension defined as sustained systolic BP > 150 mmHg or diastolic BP > 90 mmHg. (Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.) Patients requiring greater than or equal to 3 BP medications are not eligible.
+Uncontrolled hypertension defined as persistent systolic blood pressure ? 150 mmHg or diastolic blood pressure ? 100 mmHg despite current therapy.
+Systolic blood pressure (BP) not deemed clinically controlled by the investigator.
+Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ?150/90 millimeters of mercury (mmHg) at Screening and no change in antihypertensive medications within 1 week before Cycle 1/Day 1
+Uncontrolled or poorly controlled hypertension (> 160 mmHg systolic or > 100 mmHg diastolic for > 4 weeks) despite standard medical management
+Patients who are currently receiving more than one anti-hypertensive medication (Grade 3) or whose blood pressure is not well controlled are not eligible for study enrollment.
+No grade 3 or 4 hypertension (systolic blood pressure [BP] > 160 and or diastolic BP > 100) that cannot be controlled with medication prior to registration
+Current uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management) as well as prior history of hypertensive crisis or hypertensive encephalopathy.
+Uncontrolled hypertension (systolic blood pressure ? 160 mmHg or diastolic blood pressure ? 95 mmHg)
+Patients must demonstrate adequately controlled blood pressure at the time of study entry, as defined by a blood pressure =< 150/100 mmHg at study screening on at least one of two screenings conducted at least 24 hours apart; if blood pressure meets these guidelines on initial measurement, no subsequent measurement for screening is needed; blood pressure may be assessed by automated or manual methods by an appropriately trained clinician or nurse
+Participants with uncontrolled high blood pressure, defined as a blood pressure during screening of >= 160/100 despite medical management
+Uncontrolled glaucoma with intraocular pressure ? 21 mmHg
+Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and /or diastolic blood pressure > 100 mmHg)
+Normotensive or well controlled blood pressure (<140/90).
+Subject has blood pressure controlled to < 150 mmHg systolic and < 95 mmHg diastolic at screening
+Inadequately controlled hypertension (ie, systolic blood pressure [SBP] >160 mmHg or diastolic BP [DBP] >90 mmHg) at 2 separate measurements no more than 60 minutes apart during the Screening visit. Note: patients may be rescreened after adjustment of antihypertensive medications.
+Uncontrolled hypertension (blood pressure [BP] > 150/100 mmHg)
+Hypertension not controlled by medical therapy (resting systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg on at least two occasions over a 24 hour period despite optimal medical management)
+Evidence of poorly controlled hypertension which is defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management
+Uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic BP > 100 mmHg)
+Uncontrolled hypertension despite appropriate medical therapy (blood pressure of greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening period). Note: Patients may be rescreened after adjustments of antihypertensive medications
+Subject has uncontrolled hypertension, defined as a blood pressure reading >160/100 mmHg, despite maximum antihypertensive therapy.
+Unstable hypertension (blood pressure > 160/100)
+Inadequately controlled hypertension (defined as systolic blood pressure >= 150 mmHg and /or diastolic blood pressure >= 100 mmHg) within 7 days of first study treatment
+Significant medical condition other than cancer, that would prevent consistent and compliant participation in the study that would, in the opinion of the investigator, make this protocol unreasonably hazardous including but not limited to:\r\n* Any medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone once daily\r\n* History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents\r\n* Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment (systolic BP <160 mmHg or diastolic BP <95 mmHg)\r\n* Active or symptomatic viral hepatitis or chronic liver disease\r\n* Known active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection. (HIV testing is not mandatory)\r\n* History of pituitary or adrenal dysfunction\r\n* Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class III or IV heart disease or cardiac ejection fraction measurement of < 50% at baseline, or clinically significant ventricular arrhythmias within 6 months prior to treatment start.\r\n* History of seizure or any condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness =< 1 year prior to treatment start; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)\r\n* Uncontrolled diabetes mellitus\r\n* History of inflammatory bowel disease\r\n* Baseline moderate and severe hepatic impairment (Child Pugh class B & C)
+Significant cardiovascular disease (eg, myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to start of study therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure; or uncontrolled Grade ?3 hypertension (diastolic blood pressure ?100 mmHg or systolic blood pressure ?160 mmHg) despite antihypertensive therapy.
+Adequately controlled blood pressure with or without antihypertensive medications defined as blood pressure (BP) < 140/90 mmHg at screening and no change in antihypertensive mediation within 1 week prior to the screening visit
+Uncontrolled hypertension. Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy. Note that this is NOT a criterion related to particular blood pressure (BP) results at the time of assessment for eligibility, nor does it apply to acute BP excursions that are related to iatrogenic causes, acute pain or other transient, reversible causes
+Uncontrolled high blood pressure (i.e. systolic blood pressure > 180 mmHg, diastolic blood pressure > 95 mmHg)
+Adequately controlled blood pressure (BP) < 140 mmHg (systolic) and < 90 mmHg (diastolic) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of 3 antihypertensive medications; patients who are on 3 antihypertensive medications are highly recommended to be followed by a cardiologist or blood pressure specialist for management of BP while on protocol
+The patient has uncontrolled or poorly controlled hypertension (> 180 mmHg systolic or > 130 mmHg diastolic) at the time of enrollment
+Poorly controlled diabetes mellitus or hypertension (e.g., systolic > 180 mmHg or diastolic > 100 mmHg)
+Poorly controlled hypertension (systolic blood pressure [SBP] > 150 or diastolic blood pressure [DBP] > 90 despite antihypertensive therapy)
+History or evidence of cardiovascular risk including any of the following:\r\n* A QT interval corrected for heart rate using the Bazett’s formula Bazett's correction formula (QTcB) >= 460 msec on the pre-study baseline single 12 lead EKG.\r\n* History or evidence of current clinically significant uncontrolled arrhythmias (exception: patients with controlled atrial fibrillation for > 30 days prior to registration are eligible).\r\n* History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to registration.\r\n* History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system.\r\n* Treatment-refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy. In patients with no history of hypertension and a pre-study baseline blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg, a second reading should be taken at least 1 minute later, with the two readings averaged to obtain a final blood pressure (BP) measurement.\r\n* Abnormal cardiac valve morphology (>= grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.\r\n* Prior placement of an implantable defibrillator.\r\n* History of or identification on screening imaging of intracardiac metastases.
+Any history of venous or arterial thromboembolism including deep venous thrombosis or pulmonary embolism. Patients with a history of treated prior superficial or catheter associated will not be considered as significant embolism and after discussion with principal investigator (PI) will not be excluded from eligibility. Uncontrolled hypertension (diastolic blood pressure > 90 mmHg; systolic > 140 mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.
+Patients with a diagnosis of hypertension are required to have adequate blood pressure control prior to enrollment, defined as blood pressure =< 140/90 mmHg
+Uncontrolled or ongoing/active infection; patients with the following history will also not be eligible for the trial: patients with a recent history of hemorrhage or hemoptysis; patients with dehiscence or wound healing complications requiring medical intervention; patients with severe hypertension that cannot be controlled (blood pressure of > 150 systolic or > 100 diastolic mmHg) with anti-hypertensive therapy within 7 days of first dose of therapy
+Uncontrolled cardiac disease, including unstable angina, uncontrolled hypertension (i.e. sustained systolic BP >160 mmHg or diastolic BP >90 mmHg), or need to change medication due to lack of disease control within 6 weeks prior to the provision of consent;
+(Bevacizumab-related exclusion) Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg)
+Men with baseline systolic blood pressure (SBP) < 110 or heart rate (HR) < 60
+Inadequately controlled hypertension (defined as persistent systolic blood pressure (SBP) > 150 and/or diastolic blood pressure (DBP) > 100 mmHg)
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of > 150 mmHg or diastolic blood pressure [DBP] of > 90 mmHg)
+Uncontrolled hypertension defined as a systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg, with or without anti-hypertensive medications
+Systolic blood pressure (SBP) >160 mmHg or <90 mmHg at screening.
+Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
+Uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)
+Clinically significant uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
+Supine systolic blood pressure < 90 millimeter of mercury (mmHg), or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of > 20 mmHg despite medical management (eg, midodrine, fludrocortisones) in the absence of volume depletion
+Blood pressure (BP) =< 95th percentile for age, height, and gender and not receiving medication for treatment of hypertension
+Patients with significant cardiac history including:\r\n* Severe or unstable angina pectoris\r\n* Uncontrolled hypertension (defined as systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg;. Note - patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment\r\n* Atrial fibrillation or other cardiac arrhythmia requiring therapy.\r\n* Heart disease as evidenced by myocardial infarction, or aterial thrombotic events in the past 6 months\r\n* Class II-IV heart failure (as defined by New York Heart Association) or a cardiac ejection fraction measurement of less than 50% at baseline
+Has uncontrolled hypertension defined as blood pressure > 150/90 on medication(s) by 2 blood pressure readings taken at least 1 hour apart.
+Adequately controlled blood pressure (BP) < 140 mmHg (systolic) and < 90 mmHg (diastolic) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of 3 antihypertensive medications; patients who are on 3 antihypertensive medications are highly recommended to be followed by a cardiologist or blood pressure specialist for management of BP while on protocol
+Uncontrolled hypertension (HTN); sustained blood pressure (BP) greater than 150/100 mmHg
+To be performed within 10 business days prior to day 1: In patients who are to receive VRP, base systolic blood pressure (SBP) > 110; diastolic blood pressure (DBP) > 60 and baseline heart rate > 60
+Systolic blood pressure (SBP) > 160 mmHg or < 90 mmHg at screening; if initial screening SBP is outside of the eligible range, blood pressure may be re-checked after intervention; SBP must be documented as stable and within the eligible range prior to starting study drug
+Blood pressure (BP) < 150 mmHg (systolic) and < 90 mmHg (diastolic); initiation or adjustment of BP medication is permitted prior to registration provided that the average of three BP readings at a visit prior to registration is < 150/90 mmHg; NOTE: all patients with secretory pheochromocytoma or paraganglioma are REQUIRED to: 1) be evaluated in consultation by a hypertension specialist with specific experience in the management of hypertension in the setting of catecholamine-secreting tumors (usually an endocrinologist, nephrologist, or a cardiologist), and in the setting of hormone-associated hypertension) receive alpha- and beta-adrenergic blockade for at least 7-14 days prior to initiation of lenvatinib; the hypertension specialist of record for each patient should be committed to closely following the patient during the clinical study with evaluation by said specialist required at cycle 1 and 2 and thereafter on an as needed basis
+Uncontrolled hypertension (defined as average systolic blood pressure >= 140 or average diastolic blood pressure >= 90, with blood pressure measured >= 3 times in the two weeks prior to enrollment) or diabetes
+Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg) or other medical condition that could jeopardize the assessment of toxicity on study
+As determined by the treating investigator, the patient must have well-controlled blood pressure, defined as systolic blood pressure < 150 mmHg and/or diastolic blood pressure < 100 mmHg for the majority of measurements
+Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Significant cardiovascular disease, including myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism, within 6 months prior to start of study therapy; symptomatic dysrhythmias or unstable dysrhythmias requiring medical therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association Class 3 or 4 congestive heart failure; uncontrolled Grade ?3 hypertension (diastolic blood pressure ?100 mmHg or systolic blood pressure ?160 mmHg) despite antihypertensive therapy; or history of congenital prolonged QT syndrome.
+Subjects with acute PE categorized as high-risk or massive, or who are hemodynamically unstable, evidenced by a heart rate > 120 /min and a systolic blood pressure (SBP) of < 90 mmHg for more than 15 consecutive minutes or a drop in SBP of > 40 mmHg since presentation;
+Concurrent uncontrolled hypertension defined as sustained blood pressure > 95th percentile for age, height and gender (systolic or diastolic) despite optimal antihypertensive treatment within 7 days of the first dose of study treatment
+Uncontrolled hypertension as defined by systolic blood pressure (SBP) > 150 or diastolic blood pressure (DBP) > 90 on at least two separate occasions documented in the medical record; patients would be eligible if blood pressure is controlled with appropriate anti-hypertensive therapy; rescreening after this therapy has been instituted is allowed
+Patients who have uncontrolled hypertension (defined as sustained systolic blood pressure >= 160 mmHg or diastolic >= 100 mmHg)
+Uncontrolled hypertension, systolic blood pressure (SBP) > 160 or diastolic blood pressure (DBP) > 100
+Patients with chronic hypertension that is well controlled with systolic blood pressure of < 140 mmHg or diastolic blood pressure of < 90 mmHg, and in whom there has been no change in blood pressure medication in the last two weeks, are eligible
+Patients with uncontrolled hypertension (defined as sustained systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg)
+As determined by the treating investigator, the patient must have well-controlled blood pressure, defined as systolic blood pressure < 150 mmHg and/or diastolic blood pressure < 100 mmHg for the majority of measurements
+A blood pressure (BP) =< the 95th percentile for age, height, and gender and not receiving medication for treatment of hypertension
+Uncontrolled hypertension (defined as a sustained systolic pressure >= 160 mmHg and/or a diastolic pressure >= 110 mmHg
+Arterial blood gas partial pressure carbon dioxide (pCO2) < 50 mmHg
+Uncontrolled hypertension (systolic blood pressure [BP] >= 140 mmHg or diastolic BP >= 90 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
+Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg); anti-hypertensive therapy to achieve these parameters is allowable
+Patients with a cumulative lifetime history of anthracycline greater than 430 mg/m^2 are eligible, after consultation with a cardiologist, if there are none of the following cardiac risk factors:\r\n*Diabetes mellitus\r\n*History of acute coronary syndrome\r\n*Hypertension; defined as a sustained systolic blood pressure greater than 140 mmHg and/or diastolic blood pressure greater than 90 mmHg OR use of an antihypertensive medication for the indication of hypertension
+Uncontrolled hypertension (systolic blood pressure [SBP] > 170/diastolic blood pressure [DBP] > 105)
+Uncontrolled hypertension (blood pressure >= 150/90 mmHg despite optimal medical management)
+Systolic blood pressure (BP) > 160 mmHg or diastolic BP > 100 mmHg despite optimal medical management
+Uncontrolled arterial hypertension defined by blood pressure > 150 mmHg systolic and/or 100 mmHg diastolic at rest (average 3 consecutive readings at least 5 minutes apart) despite appropriate medical therapy
+CAPMATINIB EXCLUSION CRITERIA: Cardiovascular disorders including:\r\n* Symptomatic congestive heart failure (New York Heart Association class III or IV)\r\n* Personal or family history of congenital long QT syndrome\r\n* Corrected QTc > 480 msec using Fridericia correction on screening electrocardiography (ECG)\r\n* Uncontrolled hypertension (systolic pressure >= 160 mmHg or diastolic pressure >= 100 mmHg on repeated measurement) despite optimal medical management; initiation or adjustment of anti-hypertensive medications are allowed prior to screening
+CERITINIB EXCLUSION CRITERIA: Cardiovascular disorders including:\r\n* Symptomatic congestive heart failure (New York Heart Association class III or IV)\r\n* Personal or family history of congenital long QT syndrome\r\n* Corrected QTc > 480 msec using Fridericia correction on screening electrocardiography (ECG)\r\n* Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
+REGORAFENIB EXCLUSION CRITERIA: Cardiovascular disorders including:\r\n* Symptomatic congestive heart failure (New York Heart Association class III or IV)\r\n* Personal or family history of congenital long QT syndrome\r\n* Corrected QTc > 480 msec using Fridericia correction on screening electrocardiography (ECG)\r\n* Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
+ENTRECTINIB EXCLUSION CRITERIA: Cardiovascular disorders including:\r\n* Symptomatic congestive heart failure (New York Heart Association class III or IV)\r\n* Personal or family history of congenital long QT syndrome\r\n* Corrected QTc > 480 msec using Fridericia correction on screening electrocardiography (ECG)\r\n* Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
+Uncontrolled hypertension, defined as: systolic blood pressure ? 140 mmHg and/or diastolic blood pressure ? 90 mmHg;
+The patient has uncontrolled or poorly-controlled hypertension (> 160 mmHg systolic or > 100 mmHg diastolic for > 4 weeks) despite standard medical management
+A blood pressure (BP) =< the 95th percentile for age, height, and gender measured within 7 days prior to enrollment; please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP; patients with hypertension controlled on antihypertensive medications will be allowed if otherwise eligible
+Have uncontrolled hypertension (i.e., >150 and >90 for systolic blood pressure (SBP) and diastolic blood pressure (DBP) respectively). Participants with hypertension should be under treatment at study entry to ensure blood pressure control. Those requiring 3 or more antihypertensive medications should be discussed with the medical monitor.
+Patients must not have uncontrolled hypertension as defined by systolic blood pressure (SBP) >= 160 mmHg or diastolic blood pressure (DBP) >= 90 mmHg; patients whose blood pressure can be controlled medically are allowed to be rescreened once blood pressure (BP) is under control
+Hypertension not controlled by medical therapy (systolic blood pressure greater than 140 millimeter of mercury [mmHg] or diastolic blood pressure greater than 90 mmHg)
+PHASE I STUDY ELIGIBILITY CRITERIA:\r\nAdequately controlled blood pressure (systolic blood pressure [SBP] < 140 mmHg and diastolic blood pressure [DBP] < 90 mmHg) on a maximum of three antihypertensive medications
+Systolic blood pressure (SBP) > 90 (or within 10% of their baseline SBP) and diastolic blood pressure > 50 (or within 10% of their baseline diastolic blood pressure [DBP]) at time of harvest
+Subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure > 90 mmHg or systolic blood pressure > 140 mmHg; subjects may be re-screened if blood pressure is shown to be controlled with or without intervention
+Resting systolic blood pressure (BP) < 100 mmHg
+Hypertension defined as systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg despite optimal medical management
+Patients must have adequately controlled blood pressure (BP), with a BP no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of three antihypertensive medications; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or blood pressure specialist for management of blood pressure while on protocol
+Patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to Arm III
+Patients who have uncontrolled hypertension (defined as sustained systolic blood pressure >= 160 mmHg or diastolic >= 100 mmHg)
+Uncontrolled hypertension despite appropriate medical therapy (blood pressure of greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening period); Note: patients may be rescreened after adjustments of antihypertensive medications
+Patients with high risk of cardiovascular event such as severe uncontrolled hypertension (> 170/110 systemic blood pressure on therapy), or pulmonary hypertension (greater than .5 systolic blood pressure)
+Patients must have controlled blood pressure with a systolic blood pressure < 140 mmHg and diastolic < 90 mmHg (for patients with an elevated initial blood pressure (BP) reading [hypertensive range], a repeat measurement at least 2 minutes later should be performed, and the two readings should be averaged to obtain a BP reading); any hypertensive at-home blood pressure reading will be confirmed in clinic; patients on anti-hypertensive medications are eligible, if blood pressure is controlled; study drug dosing will be interrupted for any reading >= 160/100
+Uncontrolled hypertension (systolic blood pressure; [SBP] greater than 180 or diastolic blood pressure; [DBP] greater than 110)
+Uncontrolled hypertension defined as a systolic BP greater than 150 mmHg or diastolic BP greater than 90 mmHg, with or without anti-hypertensive medications. (Patients with hypertension that is well controlled on medication are eligible.)
+Patients who have uncontrolled hypertension (systolic > 140 mmHg and/or diastolic > 90 mmHg); it is permissible to start treatment for hypertension prior to randomization
+Poorly controlled hypertension (defined as systolic blood pressure of >= 160 mmHg or diastolic blood pressure of >= 90 mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure must be reassessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between antihypertensive medication initiation or adjustment and blood pressure measurement; these three values should be averaged to obtain the mean diastolic and systolic blood pressures, which must be < 140/90 mmHg in order for a patient to be eligible for the study
+History of uncontrolled hypertension, defined as blood pressure > 150/95 mmHg, or systolic blood pressure > 180 mmHg when diastolic blood pressure < 90 mmHg, on at least 2 repeated determinations on separate days within 3 months prior to study enrollment
+Inadequately controlled hypertension (defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg)
+Patients with impaired cardiac function or clinically significant cardiac diseases, including any of the following:\r\n* History or presence of serious uncontrolled ventricular or significant arrhythmias\r\n* Any of the following within 6 months prior to registration: myocardial infarction (MI), severe/unstable angina, coronary artery bypass graft (CABG), congestive heart failure (CHF), cerebrovascular accident (CVA), transient ischemic attack (TIA), pulmonary embolism (PE)\r\n* Uncontrolled hypertension (defined by a systolic blood pressure [SBP] >= 160 mmHg or diastolic blood pressure [DBP] >= 100 mmHg while on anti-hypertensive medications) or history of hypertensive crisis or hypertensive encephalopathy, stroke, TIA, symptomatic peripheral vascular disease, or grade 2 CHF
+The subject has serious intercurrent illness as determined by the treating physician, that would compromise either patient safety or study outcomes such as:\r\n* Hypertension (two or more blood pressure [BP] readings performed at screening of > 150 mmHg systolic or > 100 mmHg diastolic) despite optimal treatment\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Clinically significant cardiac arrhythmias\r\n* Untreated hypothyroidism\r\n* Uncontrolled systemic infection\r\n* Symptomatic congestive heart failure or unstable angina pectoris within 3 months prior study drug\r\n* Myocardial infarction, stroke, transient ischemic attack within 6 months\r\n* Known active malignancy (other than their glioma) except non-melanoma skin cancer or carcinoma in-situ in the cervix
+Systolic blood pressure greater than 150 mmHg or diastolic blood pressure greater than 100 mmHg
+Inadequately controlled hypertension (blood pressure: systolic > 150 mmHg and/or diastolic > 100 mmHg)
+Uncontrolled hypertension (systolic blood pressure [SBP] equal to or more than 140 or diastolic blood pressure [DBP] equal to or more than 90)
+Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication)
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg); note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP/DBP ratio must be < 140/90 mmHg
+Uncontrolled hypertension defined as systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Uncontrolled hypertension (systolic blood pressure [BP] >= 140 mmHg or diastolic BP >= 90 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
+Uncontrolled hypertension as indicated by at least 2 consecutive measurements of a resting systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg at the Screening Visit
+Uncontrolled or poorly-controlled hypertension (> 160 mmHg systolic or > 100 mmHg diastolic for > 4 weeks) despite standard medical management
+Inadequately controlled hypertension (defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg); to control hypertension, the addition or increase of standard of care antihypertensive regimen is allowed
+Inadequately controlled hypertension (defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg) despite antihypertensive medication, or prior history of hypertensive crisis or hypertensive encephalopathy
+Inadequately controlled hypertension (defined as systolic blood pressure > 140 and/or diastolic blood pressure > 90 mmHg); initiation of antihypertensive is permitted provided adequate control is documented over at least 1 week prior to day 1 of study drug
+Adequately controlled blood pressure
+Uncontrolled high blood pressure defined as systolic BP greater than or equal to 150 mmHg or diastolic BP greater than or equal to 100 mmHg with or without anti-hypertensive medication. Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.
+uncontrolled hypertension (systolic BP> 180 mmHg or diastolic BP > 100 mmHg despite antihypertensive treatment);
+Supine systolic blood pressure < 100 mmHg or supine diastolic blood pressure < 50 mmHg at screening and baseline
+Uncontrolled hypertension (untreated systolic blood pressure > 160 mmHg, or diastolic blood pressure > 95 mmHg)
+Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria)
+A common skin contaminant cultured from 2 or more blood cultures drawn on the same or consecutive calendar days from a subject with fever (greater than 38.0 degrees C), chills, or hypotension (systolic blood pressure less than 90 mmHg);
+Uncontrolled hypertension on anti-hypertensive medication (systolic blood pressure >150 mmHg or diastolic blood pressure >95 mmHg)
+Patients with uncontrolled hypertension (requirement for more than 2 blood pressure [BP] medications or grade 2 or higher BP elevation while on adequate doses of not more than 2 antihypertensive agents) are excluded from the study
+Mean arterial blood pressure (BP) of less than 70 mmHg
+Blood pressure < 160/100 mmHg
+Inadequately controlled hypertension (systolic blood pressure [SBP] > 150mmHg, diastolic blood pressure [DBP] > 100mg Hg)
+No history of the following\r\n* Prior brain metastases\r\n* Leptomeningeal disease\r\n* Seizures\r\n* Class 3 or 4 congestive heart failure\r\n* Uncontrolled hypertension (systolic blood pressure [BP] > 170 mmHg or diastolic BP > 105 mmHg) despite optimal medical management\r\n* Major surgery =< 4 weeks of registration
+Inadequately controlled hypertension (systolic blood pressure of > 150 mmHg or diastolic pressure > 90 mmHg on anti-hypertensive medications)
+Uncontrolled arterial hypertension despite appropriate medical therapy (systolic blood pressure > 160 or diastolic blood pressure > 100)
+Have uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic BP > 100 mmHg).
+Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding episodes). Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator; systolic blood pressure higher than 150 millimeter of mercury (mmHg) or diastolic blood pressure higher than 90 mmHg found on 2 separate occasions separated by 1 week, despite adequate therapy, will be defined as uncontrolled hypertension; uncontrolled diabetes mellitus (despite therapeutic, compliance intervention) as defined by a hemoglobin A1c (HbA1c) level more than 8% and/or occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to the first dose of study drug.
+Patients with systolic blood pressure (SBP) >= 140 mmHg or diastolic blood pressure (DBP) >= 90 mmHg at the screening visit are ineligible; patients with an initial clinic blood pressure (BP) >= 140/90 mmHg may be included if SBP < 140 mmHg and DBP < 90 mmHg is confirmed in two subsequent BP measurements on the same day
+Resting systolic blood pressure (BP) < 100 mmHg
+Hypertension defined as systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg despite optimal medical management
+Uncontrolled arterial hypertension defined as persistent elevation of systolic blood pressure >= 150 mmHg or diastolic blood pressure >= 100 mmHg despite medical treatment
+Adequately controlled blood pressure; (defined as systolic blood pressure [SBP] of < 140 mmHg and diastolic blood pressure [DBP] of < 90 mmHg) on maximum of three antihypertensive medications; participants must have a blood pressure (BP) of < 140/90 taken in the clinic or hospital setting by a medical professional within 2 weeks prior to starting on study; it is strongly recommended that participants who are on 3 antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on study
+Patients with hypertension on medical management must have systolic blood pressure < 150 mmHG or diastolic pressure < 90 mmHG at study entry
+Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on maximum of three antihypertensive medications; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; it is strongly recommended that patients who are on three antihypertensive medications must be actively followed by a cardiologist or a primary care physician for management of BP while on protocol; patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to cediranib alone and the combination of olaparib and cediranib arms
+Poorly-controlled hypertension as defined blood pressure (BP) > 150/100 mmHg, or systolic (S) BP > 180 mmHg when diastolic (D) BP < 90 mmHg, on at least 2 repeated determinations on separate days within 3 months prior to study enrollment
+Uncontrolled hypertension (defined as a systolic pressure ? 160 mmHg and/or a diastolic pressure ? 110 mmHg).
+Hypertension not controlled by medical therapy (systolic blood pressure [BP] greater than 160 millimeters of mercury [mmHg] or diastolic blood pressure great than 100 mmHg)
+Inadequately controlled hypertension (defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure > 90 mmHg)
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 150 mmHg and/or diastolic blood pressure [DBP] of >= 90 mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study registration
+Systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg
+Subjects who have a history or current evidence of uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic blood pressure > 95 mmHg at screening despite optimal medical management; subjects with a history of mild to moderate hypertension are eligible at the investigator’s discretion if the hypertension is adequately controlled by antihypertensive treatment used at a stable dose for at least 2 weeks before the start of study treatment
+Uncontrolled hypertension (HTN) despite medical management (blood pressure [BP] >= 160/100)
+Cardiac conditions as follows:\r\n* Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 12 months prior to first study drug administration\r\n* Class II-IV New York Heart Association (NYHA) congestive heart failure\r\n* Uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg and diastolic BP > 90 mmHg for 24 hours) despite optimal medical management; blood pressure must be below 140/90 mmHg at screening; subjects with a history of hypertension who are receiving treatment with calcium channel blockers that are cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) substrates should be changed to an alternative antihypertensive medication prior to first study drug administration\r\n* Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin\r\n* Corrected QT (QTc) (Frederica) prolongation > 480 msec\r\n* Subjects with valvular heart disease Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) grade 2\r\n* Known left ventricular ejection fraction (LVEF) < 50%
+Uncontrolled high blood pressure (i.e., systolic blood pressure >= 160 mmHg, diastolic blood pressure >= 90 mmHg)
+Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria)
+Hemodynamic parameters:\r\n* Systolic blood pressure < 140 mmHg\r\n* Diastolic blood pressure < 90 mmHg
+For patients receiving antihypertensive medication:systolic blood pressure < 120 mmHg\n             and/or diastolic blood pressure < 70 mmHg at screening.
+Blood pressure (BP) > 140 mmHg (systolic) and > 90 mmHg (diastolic); initiation or adjustment of BP medication is permitted prior to registration provided that the average of three BP readings at a visit prior to registration is < 140/90 mmHg
+Blood pressure =< 140/90 within 10 days of registration (must be taken and recorded by a health care professional); Note: if the systolic blood pressure is > 140 and/or diastolic blood pressure is > 90 at the time of registration, the patient’s blood pressure must be controlled; systolic blood pressure must be < 140 and diastolic blood pressure must be < 90 on at least 2 separate measurements prior to the start of treatment, and the treating physician must believe that this is feasible in order to enroll the patient
+Inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)
+Uncontrolled hypertension, defined as systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Patients must have blood pressure measured within 14 days prior to registration; patients must not have uncontrolled hypertension (defined as blood pressure > 160 mmHg systolic and > 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart) despite appropriate medical therapy; Note: patients may be rescreened after adjustments of antihypertensive medications
+No uncontrolled or poorly controlled hypertension despite standard medical management(e.g., consistently systolic blood pressure [SBP] > 160 and diastolic blood pressure [DBP] > 90 mmHg)
+Uncontrolled hypertension with systolic blood pressure >160 mmHg
+For Cohort C: Has hypotension (systolic blood pressure <86 millimeters of mercury [mmHg]) or uncontrolled hypertension (systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg) at the screening visit
+Poorly controlled hypertension (defined as systolic blood pressure [systolic blood pressure (SBP) of >= 150 mmHg or diastolic blood pressure (DBP)] of >= 90 mmHg)
+Patients who have uncontrolled or poorly-controlled hypertension (> 139 mmHg systolic or > 89 mmHg diastolic for > 4 weeks) despite standard medical management
+Patient must have a systolic blood pressure =< 140 mmHg and diastolic blood pressure must be =< 90 mmHg, measured within 4 weeks prior to randomization; initiation or adjustment of anti-hypertensives prior to starting study treatment is allowed
+Uncontrolled hypertension (systolic blood pressure [BP] greater than [>] 150 millimeters of mercury [mmHg] and/or diastolic BP > 100 mmHg), unstable angina, congestive heart failure of any New York Heart Association classification, serious cardiac arrhythmia that requires treatment with the exceptions of atrial fibrillation and paroxysmal supraventricular tachycardia, and history of myocardial infarction within 6 months of enrollment
+Poorly controlled hypertension, defined as systolic blood pressure (SBP) of >= 140 mmHg or diastolic blood pressure (DBP) of >= 90mmHg; Note: screening/baseline blood pressure (BP) must be assessed with three measurements at approximately 2-minute intervals; the mean SBP/DBP values from the three readings must be < 140/90 mmHg in order for a subject to be eligible for the study; if the subject’s initial screening SBP/DBP is >= 140/90 mmHg, initiation or adjustment of antihypertensive medication(s) is permitted in an attempt to control the subject’s BP level to below 140/90 mmHg; optimal blood pressure control must be achieved before registration and monitored
+Poorly controlled hypertension (defined as systolic blood pressure of >= 140 mmHg or diastolic blood pressure of >= 90 mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure must be reassessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between antihypertensive medication initiation or adjustment and blood pressure measurement; these three values should be averaged to obtain the mean diastolic and systolic blood pressures, which must be < 140/90 mmHg in order for a patient to be eligible for the study
+Blood pressure (BP) ? 140/90 millimeter of mercury (mmHg) at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1.
+Uncontrolled hypertension: systolic blood pressure >= 160, diastolic blood pressure >= 90
+Patients are ineligible if they have inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)
+Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy
+Uncontrolled blood pressure (systolic pressure greater than 150 mmHg or diastolic pressure greater than 90 mmHg on repeated measurements).
+Systolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg.
+Subjects with a blood pressure of >140/90 mmHg.
+Have uncontrolled hypertension (systolic blood pressure greater than 150 or diastolic blood pressure greater than 100) or history of congestive heart failure (AHA Grade 2 or higher).
+Uncontrolled hypertension (defined as a systolic pressure ? 160 mmHg and/or a diastolic pressure ? 110 mmHg).
+Systolic Blood Pressure (SBP) >160 or <90 mmHg
+Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension (blood pressure ? 160/95 mmHg).
+Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg); anti-hypertensive therapy to maintain a systolic blood pressure < 150 mmHg and/or diastolic blood pressure < 100 mmHg is permitted
+uncontrolled hypertension (systolic BP ? 139 mmHg or diastolic BP ? 89 mmHg) at screening, despite optimal antihypertensive therapy,
+Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1.
+Uncontrolled arterial hypertension (systolic blood pressure > 155 mmHg or diastolic > 95 mmHg) despite appropriate medical therapy
+Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Hypertensive patients with uncontrolled blood pressure.
+Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study as so judged by the treating physician; examples include but are not limited to:\r\n* Severely impaired lung function (e.g. use of home O2, history of idiopathic lung disease [ILD], any evidence of ILD on scan)\r\n* Active (acute or chronic) severe infections requiring treatment with I.V. antibiotics\r\n* Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis\r\n* Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); NOTE: initiation or adjustment of anti-hypertensive medication(s) is permitted prior to study entry; following anti-hypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP/DBP ratio must be < 140/90 mmHg in order for a subject to be eligible for the study
+Treatment refractory hypertension defined as a blood pressure of systolic >140 millimeter of mercury (mmHg) and/or diastolic >90 mmHg which cannot be controlled by antihypertensive therapy.
+Patients with pre-existing hypertension should be on a stable antihypertensive regimen and have a blood pressure =< 150/100 mmHg at the time of enrollment
+Patients with inadequately controlled systemic hypertension (systolic blood pressure [SBP] and/or\r\ndiastolic blood pressure [DBP] > 95th percentile for age and height)\r\n* Patients with a prior history of hypertensive crisis and/or hypertensive encephalopathy\r\nIf a blood pressure (BP) measurement prior to registration is > 95th percentile for age and height, it must be rechecked and documented to be < 95th percentile for age and height prior to registration; if a patient falls between the height or weight percentiles, site should average the value as appropriate; for patients >= 18 years, use adult normal ranges for blood pressure; patients with hypertension are eligible if their blood pressures become < 95th percentile after anti-hypertensive medications
+Adequately controlled blood pressure
+Uncontrolled arterial hypertension defined as persistent elevation of systolic blood pressure >= 150 mmHg or diastolic blood pressure >= 100 mmHg despite current therapy
+Inadequately controlled hypertension (defined as average systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)
+Have uncontrolled hypertension, as defined in CTCAE Version 4.0, prior to initiating study treatment, despite antihypertensive intervention. CTCAE Version 4.0 defines uncontrolled hypertension as Grade >2 hypertension; clinically, the participant continues to experience elevated blood pressure (systolic >160 millimeters of mercury [mmHg] and/or diastolic >100 mmHg) despite medications.
+Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg [NCI-CTCAE v4.0] on repeated measurement) despite optimal medical management
+Uncontrolled hypertension – blood pressure >= 150/90 mmHg despite medical therapy
+Uncontrolled hypertension (systolic blood pressure [SBP] > 170/ diastolic blood pressure [DBP] > 105)
+Subjects who have a history or current evidence of uncontrolled hypertension defined as systolic blood pressure ?160 mmHg or diastolic blood pressure ?100 mmHg at screening despite optimal medical management.
+Hypotension as indicated by systolic blood pressure < 86 mmHg on 2 consecutive measurements at the Screening visit.
+Uncontrolled hypertension as indicated by systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg on 2 consecutive measurements at the Screening visit.
+Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment\r\n* Sustained systolic blood pressure > 160 or diastolic blood pressure > 100 despite medical therapy; sustained blood sugar > 300 despite medical therapy\r\n* Chronic hypertension or diabetes on appropriate medical therapy does not constitute an exclusion criterion
+Patients who have uncontrolled hypertension (defined as sustained systolic blood pressure >= 160 mmHg or diastolic >= 100 mmHg)
+Systolic blood pressure greater than 160 mmHg or less than 90 mmHg at screening
+Patients with uncontrolled hypertension (systolic blood pressure [SBP] > 155, diastolic blood pressure [DBP] > 90), unstable coronary disease (unstable angina, evidence of congestive heart failure [CHF], or myocardial infarction [MI] within 6 months of study)
+Uncontrolled hypertension; (systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
+Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg, despite optimal medical management.
+Willingness and ability to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients
+Participants may not have any evidence of ongoing inadequately controlled hypertension (defined as a systolic blood pressure [BP] of > 140 mmHg or a diastolic BP of > 90 mmHg); patients with hypertension may not be on more than three antihypertensive medications for management of their blood pressure (medications that combine two anti-hypertensives into one are considered as two medications); it is strongly recommended that patients who require three antihypertensive medications for baseline management of pre-existing hypertension be actively followed by a cardiologist or blood pressure specialist for management of BP while on protocol
+Uncontrolled hypertension (blood pressure >160 mmHg systolic and >100 mmHg diastolic).
+Patient with impaired cardiac function or any clinically significant uncontrolled cardiac disease, and/or, cardiac repolarization abnormality, including any of the following: Clinically significant heart disease such as CHF requiring treatment (NYH grade ? 2), history of angina pectoris, myocardial infarction, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to study entry, documented cardiomyopathy, or left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO). Uncontrolled systolic blood pressure (SBP) ?160 mmHg and/or diastolic blood pressure (DBP) ?100 mmHg, with or without anti-hypertensive medication. Initiation or adjustment of antihypertensive medication (s) is allowed prior to screening, Systolic blood pressure (SBP) <90 mmHg Standard 12-lead ECG values defined as the mean of the triplicate ECGs and assessed by central laboratory
+Controlled blood pressure defined as a systolic blood pressure =< 140 mmHg and diastolic blood pressure =< 90 mmHg on no more than three anti-hypertensive agents; drug formulations containing two or more anti-hypertensive agents will be counted based on the number of active agents in each formulation
+Patients with uncontrolled hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg)
+Hypertension as defined by systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg despite optimal medical management
+Patients with poorly controlled hypertension (systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 90 mmHg or higher) are ineligible; patients with a history of hypertension (HTN) and stable blood pressure (BP) < 140/90 on anti-HTN regimen are eligible
+Inadequately controlled hypertension (i.e., systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) (patients with values above these levels must have their blood pressure controlled with medication prior to starting treatment).
+Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication)
+Significant active cardiovascular disease including:\r\n* Uncontrolled high blood pressure (i.e., systolic blood pressure > 180 mmHg, diastolic blood pressure > 95 mmHg)\r\n* Grade 3 or higher valvular disease\r\n* Grade 3 or higher atrial fibrillation\r\n* Grade 3 or higher bradycardia\r\n* Endocarditis\r\n* Pulmonary embolism\r\n* Recent cerebrovascular accident within 6 months prior to enrollment
+No patients with inadequately controlled hypertension (defined as a blood pressure of >= 150 mmHg systolic and/or >= 90 mmHg diastolic), or any prior history of hypertensive crisis or hypertensive encephalopathy
+Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Controlled blood pressure (systolic blood pressure < 140 and diastolic blood pressure < 90) on no more than three anti-hypertensive agents; drug formulations containing two or more anti-hypertensive agents will be counted based on the number of active agents in each formulation
+Diastolic blood pressure above the 95% for age in children and > 160 mmHg systolic or > 100 mmHg diastolic in adults on at least 2 of 3 measurements with an appropriate-size cuff who are unable to achieve blood pressure control with optimal anti-hypertensive therapy; patients who are treated with antihypertensive medications with good response are eligible
+Known impaired cardiac function or clinically significant cardiac disease such as ventricular arrhythmia requiring therapy, congestive heart failure and uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg on antihypertensive medications).
+Subject has uncontrolled hypertension as indicated by a resting systolic blood pressure > 160 millimeter of mercury (mmHg) or diastolic blood pressure > 100 millimeter of mercury (mmHg) at Screening.
+Unstable hypertension defined as a systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management
+Patients must have controlled blood pressure with a systolic blood pressure < 140 mmHg and diastolic < 90 mmHg; anti-hypertensive medications are permitted
+Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
+Blood pressure well controlled and must have systolic < 140 mmHg and diastolic < 90 mmHg
+Systolic blood pressure >160 or <90 mmHg
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg)\r\nNote: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP / DBP ratio must be < 140/90 mmHg (or 150/90 mm Hg, if approved by principal investigator [PI] and the quality assurance monitor [QAM]) in order for a patient to be eligible for the study
+Has existing uncontrolled arterial hypertension (systolic blood pressure [SBP] ?150 mmHg or diastolic blood pressure [DBP] ?100 mmHg) despite appropriate medical therapy
+Adequate blood pressure (BP) control with or without antihypertensive medications
+Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
+History of any one or more of the following cardiovascular conditions within the past 6 months: \r\n* Cardiac angioplasty or stenting \r\n* Myocardial infarction \r\n* Unstable angina \r\n* Coronary artery bypass graft surgery \r\n* Symptomatic peripheral vascular disease\r\n* Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)\r\n* Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >=140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be =< 140/90 mmHg in order for a subject to be eligible for the study\r\n* History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: subjects with recent DVT who have been treated with therapeutic anticoagulating agents for at least 6 weeks are eligible
+Subjects with uncontrolled hypertension (systolic blood pressure [BP] >180 mmHg or diastolic BP >100 mmHg) at screening are excluded. Subjects requiring 2 or more medications to control hypertension are eligible with Medical Monitor approval.
+Patients with inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg) are not eligible for participation
+Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than 150/90 mmHg at screening and no change in antihypertensive medications within 1 week before Cycle 1/Day 1 (C1D1).
+Uncontrolled hypertension (systolic blood pressure [SBP] > 170/diastolic blood pressure [DBP] > 105)
+Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version [v]4.0) on repeated measurement) despite optimal medical management
+No evidence of preexisting uncontrolled hypertension; if the patient has a history of or elevated blood pressure at baseline then they must have controlled hypertension documented and confirmed by 2 consecutive blood pressure readings taken within 1 hour; the baseline systolic blood pressure readings must be =< 140 mm Hg, and the baseline diastolic blood pressure readings must be =< 90 mm Hg\r\n* Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean systolic blood pressure (SBP)/diastolic blood pressure (DBP) ratio must be < 140/90 mmHg (OR 150/90 mm Hg, if this criterion is approved by the Huntsman Cancer Institute [HCI] Data Safety Monitoring Committee [DSMC] Chair or Co-chair) in order for a subject to be eligible for the study
+Poorly controlled hypertension, defined as systolic blood pressure >= 150 mmHg or diastolic blood pressure of >= 95 mmHg
+Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management).
+For patients with hypertension at baseline with a systolic pressure greater than 140 or a diastolic pressure greater than 90
+Patient must not have poorly controlled hypertension (defined as systolic blood pressure of >= 140 mmHg or diastolic blood pressure of >= 90 mmHg); initiation or adjustment of antihypertensive medications is permitted prior to study entry; blood pressure must be re-assessed on two occasions that are separated by a minimum of one hour; on each of these occasions, the mean (of 3 readings) from each assessment must be < 140/90 mmHg for a patient to be eligible for this study
+Clinically significant cardiovascular disease including myocardial infarction within 6 months, uncontrolled angina within 3 months, congestive heart failure New York Heart Association (NYHA) class 3 or 4, uncontrolled hypertension as indicated by systolic blood pressure > 160 mmHg or diastolic blood pressure > 95 mmHg at the screening visit
+Generally well-controlled blood pressure with systolic blood pressure =< 140 mmHg AND diastolic blood pressure =< 90 mmHg prior to enrollment; the use of anti-hypertensive medications to control hypertension is permitted
+Uncontrolled hypertension (blood pressure ? 150/90 mmHg despite optimal medical management)
+Blood pressure < 160/90
+Vital signs within the ranges: systolic blood pressure 80-150 mmHg , diastolic blood pressure 50-100 mmHg, pulse rate 40-100 bpm, oral body temperature 35.0-37.5°C.
+Patients must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry provided that the average of three BP readings at a visit prior to enrollment is less than 140/90 mmHg
+Patients with poorly controlled hypertension (systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 91 mmHg or higher) are ineligible
+History or evidence of cardiovascular risk (LVEF < LLN; QTcB >= 480 msec; blood pressure or systolic >=140 mmHg or diastolic >= 90 mmHg which cannot be controlled by anti-hypertensive therapy)
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 150 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be < 150/90 mmHg in order for a subject to be eligible for the study
+Blood pressure that is not controlled despite > 2 oral agents (systolic blood pressure [SBP] > 160 and diastolic blood pressure [DBP] > 90 documented during the screening period with no subsequent blood pressure readings < 160/100)
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be < 140/90 mmHg in order for a subject to be eligible for the study
+Inadequately controlled hypertension (systolic blood pressure of > 150 mmHg or diastolic pressure > 100 mmHg on anti-hypertensive medications); Note: history of hypertensive crisis or hypertensive encephalopathy not allowed
+Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)
+Systolic blood pressure (SBP) > 110 mmHg; diastolic blood pressure (DBP) >= 60 mmHg
+Uncontrolled hypertension (systolic blood pressure [sBP] > 150 mmHg and/or diastolic BP > 100 mmHg, found on two consecutive measurements separated by a one week period of time despite adequate medical support)
+Patients’ baseline blood pressure must be adequately controlled with or without antihypertensive medications prior to enrollment (systolic < 145 mmHg, diastolic < 90 mmHg)
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure must be re-assessed prior to start of study therapy; the mean SBP/DBP values must be < 140/90 mmHg (OR 150/90 mmHg, if this criterion is approved by Safety Review Team) in order for a subject to be eligible for the study
+Uncontrolled hypertension defined by systolic blood pressure (SBP) > 140 or diastolic blood pressure (DBP) > 90 despite titration of anti-hypertensive medications
+Blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry provided that the average of three BP readings on baseline assessment prior to enrollment is less than 140/90 mmHg
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be < 140/90 mmHg in order for a subject to be eligible for the study
+Uncontrolled hypertension defined as systolic blood pressure (BP) >= 140 mmHg or diastolic BP >= 90 mmHg with or without antihypertensive medication, based on a mean of 3 measurements at approximately 2-minute intervals
+Patients with inadequately controlled hypertension (defined as a blood pressure of > 150 mmHg systolic and/or > 100 mmHg diastolic on medication), or any prior history of hypertensive crisis or hypertensive encephalopathy
+Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)
+Hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg OR diastolic blood pressure [DBP] of >= 90 mmHg) in spite of optimal medical management; note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; in this event, blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be < 140/90 mmHg in order for a subject to be eligible for the study
+No evidence of preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart; the baseline systolic blood pressure readings must be =< 140, and the baseline diastolic blood pressure readings must be =< 90; patients whose hypertension is controlled by antihypertensive therapies are eligible
+Inadequately controlled hypertension (i.e. systolic blood pressure [SBP] > 180 mmHg or diastolic blood pressure [DBP] > 100 mmHg)
+Uncontrolled hypertension (defined as systolic blood pressure [SBP] and/or diastolic blood pressure [DBP] > 95th percentile for age)
+Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication)
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg); initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure must be re-assessed on two occasions that are separated by a minimum of 24 hours; the mean SBP/DBP values from each blood pressure assessment must be < 140/90 mmHg in order for a subject to be eligible for the study
+EXPANSION COHORT ONLY: Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg); initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure must be re-assessed on two occasions that are separated by a minimum of 24 hours; the mean SBP/DBP values from each blood pressure assessment must be < 140/90 mmHg in order for a subject to be eligible for the study
+Blood pressure of > 150/100 mmHg, history of hypertensive crisis or hypertensive encephalopathy
+b. Uncontrolled hypertension (systolic blood pressure > 150 mm Hg or diastolic blood pressure > 90 mmHg despite optimal medical management)
+Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ?150/90 mmHg at Screening and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1 (C1/D1)
+Patients may not have any evidence of pre-existing inadequately controlled hypertension (defined as a systolic blood pressure [BP] of > 140 mmHg or a diastolic BP of > 90 mmHg), and must have a normal blood pressure (=< 140/90 mmHg) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of three antihypertensive medications; patients who are on three antihypertensive medications must be actively followed by a cardiologist or blood pressure specialist for management of blood pressure while on protocol
+Uncontrolled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg on medication)
+Systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg despite optimal medical management
+Adult patients with hypertension not controlled by medical therapy (hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management); pediatric patients must have blood pressure (BP) within normal limits (WNL) for age; NOTE: blood pressure within the upper limit of normal is defined as: blood pressure =< the 95th percentile for age, height, and gender, and not be receiving medication for treatment of hypertension
+Uncontrolled hypertension (blood pressure [BP] > 100 diastolic despite treatment with maximum doses of at least 3 simultaneous or concurrent antihypertensives over a 2-month period)
+Controlled blood pressure (defined as systolic BP </= 140 mmHg and diastolic </= 85 mmHg)
+Uncontrolled hypertension defined as systolic blood pressure > 140 mmHg or diastolic pressure > 85 mmHg despite optimal medical management
+Subject has severe or uncontrolled systemic diseases including uncontrolled hypertension (blood pressure > 150/100 mmHg) or active bleeding diatheses.
+Systolic blood pressure 80-180 mmHg
+Significant uncontrolled pulmonary hypertension defined as: Pulmonary artery peak systolic pressure > 55 mmHg by echocardiogram, or pulmonary artery peak systolic pressure 45-55 mmHg by echocardiogram and mean pulmonary artery pressure by right heart catheterization exceeding 25 mmHg at rest (or 30 mmHg with exercise); or NYHA/World Health Organization (WHO), Class III or IV
+Uncontrolled hypertension (blood pressure greater than 140/90 mmHg on at least 2 measurements on sequential visits, despite blood pressure medication)
+Hypertension, defined for adults by SBP ? 160 mmHg and/or DBP ? 100 mmHg at baseline (or screening if baseline visit is skipped), and for pediatric patients by blood pressure greater than the 95th percentile for age, sex, and height (see Table 16-1). Additionally, patients who were started on antihypertensive medication after HSCT or who have received additional antihypertensive medication after HSCT will be eligible, even if they don't have elevated blood pressure.
+Seated systolic blood pressure 90 to 180 mmHg
+Uncontrolled hypertension defined as systolic blood pressure ?160 mmHg and/or diastolic blood pressure ?100 mmHg confirmed upon repeated measures
+Uncontrolled hypertension defined as systolic blood pressure ? 160 mmHg and/or diastolic blood pressure ? 100 mmHg confirmed upon repeated measures
+Uncontrolled hypertension as indicated by at least 2 consecutive measurements of a resting systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg at the screening visit.
+Uncontrolled hypertension defined as systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management
+Supine systolic blood pressure < 100 mmHg or diastolic blood pressure < 50 mmHg.
+Patients must have blood pressure no greater than 140 mmHg (systolic blood pressure) and 90 mmHg (diastolic blood pressure) for eligibility; initiation or adjustment of antihypertensive medications is permitted prior to study entry provided that the average of three blood pressure measurements at enrollment visit is less than 140/90 mmHg
+Blood pressure ? 140/90 mmHg.
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of ? 150 mmHg or diastolic blood pressure [DBP] of ? 90 mmHg) on more than one occasion
+Inadequately controlled hypertension (defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure > 90 mmHg)
+Severe hypertension (diastolic blood pressure [BP] > 100 on medication)
+Have uncontrolled hypertension (systolic blood pressure [SBP] greater than140 mmHg or diastolic blood pressure [DBP] greater than 90 mmHg) despite optimal medical management.
+Hypotension at the time of screening (i.e., systolic blood pressure less than 110 mmHg. Diastolic blood pressure less than 60 mmHg)
+Uncontrolled hypertension (systolic blood pressure > 150 or diastolic blood pressure > 100)
+Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ? 140 mmHg or diastolic blood pressure (DBP) of ? 90mmHg].
+Confirmed systolic blood pressure < 100 mmHg or diastolic blood pressure < 50 mmHg
+Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Participants with uncontrolled sustained hypertension which will be defined as systolic blood pressure > 140, and diastolic blood pressure > 90, even with use of anti-hypertensive medications
+Uncontrolled hypertension (systolic blood pressure [BP] ? 160 millimeters of mercury [mmHg] or diastolic BP ? 95 mmHg).
+Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
+Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg, despite optimal medical management
+Mean arterial blood pressure (BP) of less than 70 mmHg.
+Intraocular pressure > 21 mmHg as measured by tonometry
+History of uncontrolled hypertension (systolic > 150 mmHg or diastolic pressure > 90 mmHg) despite optimal medical management
+6. Uncontrolled hypertension (diastolic ? 100 mmHg) or hypotension (systolic ? 90 mmHg).
+Uncontrolled hypertension defined as systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg, despite optimal medical management and stable antihypertensive treatment for more than 7 days before the first dose of study drug
+Subjects with uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg) are excluded. Subjects requiring 2 or more medications to control hypertension are eligible with Medical Monitor approval.
+Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension (persistent systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg on antihypertensive medications) or arrhythmia, congestive heart failure (NYHA Class III or IV) related to primary cardiac disease, ischemic or severe valvular heart disease, or myocardial infarction within 6 months prior to the first dose of study treatment
+Participants must have a baseline blood pressure of 160/90 or less; participants requiring medicines to control blood pressure are eligible
+Uncontrolled high blood pressure (that is, systolic blood pressure >180 millimeter of mercury [mmHg], diastolic blood pressure >95 mmHg).
+Uncontrolled hypertension, defined as SBP ? 140 mmHg and/or DBP ? 90 mmHg with optimized anti-hypertensive therapy
+Patients must have resting blood pressure (BP) no greater than 140 mmHg (systolic) or 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry
+History of uncontrolled hypertension, defined as systolic blood pressure > 150 mmHg while simultaneous diastolic blood pressure > 100 mmHg, or systolic blood pressure > 180 mmHg when diastolic blood pressure < 90 mmHg, on at least 2 repeated determinations on separate days within 3 months prior to study enrollment
+Uncontrolled arterial hypertension despite appropriate medical therapy (defined as systolic blood pressure > 160 or diastolic blood pressure > 100)
+Abnormal systolic blood pressure, diastolic blood pressure and/or heart rate
+Uncontrolled hypertension: systolic blood pressure of > 140 mmHg or diastolic blood pressure of > 90 mmHg documented on 2 consecutive measurements taken at least 24 hours apart
+Patients with New York Heart Association (NYHA) grade 2 or higher congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, or arterial thrombotic event with the past 12 months, uncontrolled hypertension (systolic blood pressure > 150 and/or diastolic blood pressure > 100 on antihypertensive medications; patients not on medication for high blood pressure who are found to have systolic blood pressure [SBP] > 150 and/or diastolic blood pressure [DBP] > 100 should have 3 documented episodes of elevated blood pressure before being considered ‘uncontrolled’, if they have 3 documented episodes of elevated blood pressure, then can be started on antihypertensive medications; patients currently on antihypertensive medications with elevated blood pressures as defined above may have their medications adjusted; if patients have persistent [3 episodes] of high blood pressure despite medication adjustment they will be considered ineligible for study participation; each measured episode should be 24 hours apart), prior history of hypertensive crisis or hypertensive encephalopathy, uncontrolled or clinically significant arrhythmia, grade II or greater peripheral vascular disease or prior history of stroke or transient ischemic attack (TIA); patient must have a pretreatment oncocardiology echocardiogram with left ventricular ejection fraction (LVEF) above lower limit of normal
+Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg on 2 or more consecutive blood pressure readings, despite optimal medical management
+Controlled blood pressure, defined as blood pressure =< 140/90 on average (3 separate readings taken at screening visit in a relaxed clinical environment and averaged)
+Uncontrolled hypertension despite appropriate medical therapy (blood pressure [BP] of greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening visit); note: patients may be rescreened after adjustment of antihypertensive medications
+Treatment refractory hypertension defined as systolic blood pressure >140 millimetres of mercury (mmHg) and/or diastolic blood pressure >90 mmHg which cannot be controlled by antihypertensive therapy
+Hypotension (systolic blood pressure < 86 mmHg or bradycardia with a heart rate of <50 beats per minute on the ECG., unless pharmaceutically induced and thus reversible (i.e. beta blockers).
+Uncontrolled hypertension as indicated by a resting systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg
+Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or diastolic blood pressure greater than 100mmHg); or history of congestive heart failure (equal to or greater than Grade 2).
+Poorly controlled hypertension (defined as systolic blood pressure of>=150 millimeter of mercury (mmHg) or diastolic blood pressure of >100 mmHg based on a mean of three measurements at approximately 2-minute intervals)
+Adequate Blood Pressure Control defined as: Blood pressure <= the 95th percentile for age, height, and gender.
+Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
+Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg) despite medical treatment; patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertension treatment
+Subjects must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry provided that the average of three BP readings at the time of enrollment is =< 140/90 mmHg
+Grade 3 hypertension (systolic blood pressure [SBP] >= 160 mmHg and/or diastolic blood pressure [DBP] >= 100 mmHg despite maximal medical therapy)
+Patients must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry provided that the BP reading prior to enrollment is no greater than 140/90 mmHg
+Adequate blood pressure defined as:\r\n* A blood pressure (BP) =< the 95th percentile for age, height, and gender measured; adequate blood pressure can be achieved using medication for treatment of hypertension
+Patients not achieving adequate blood pressure in spite of antihypertensive therapy for control of blood pressure
+Inadequately controlled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 90 mmHg despite antihypertensive medication)
+Patients must have normal blood pressure or well-controlled hypertension.
+Generally well-controlled blood pressure with systolic blood pressure =< 140 mmHg AND diastolic blood pressure =< 90 mmHg prior to enrollment; the use of antihypertensive medications to control hypertension is permitted
+Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
+Inadequately controlled hypertension (systolic blood pressure of > 150 mmHg or diastolic pressure > 100 mmHg on anti-hypertensive medications)
+Uncontrolled hypertension: systolic blood pressure > 140 mmHg or diastolic blood pressure >90 mmHg on 2 or more antihypertensive medications, documented on 2 consecutive measurements taken at least 24 hours apart.
+Inadequately controlled hypertension (defined as systolic blood pressure >= 140 and/or diastolic blood pressure >= 90 mmHg on antihypertensive medications), any prior history of hypertensive crisis or hypertensive encephalopathy, and history of myocardial infarction or unstable angina within 6 months prior to study enrollment
+Poorly controlled hypertension [defined as systolic blood pressure of > or = 140 mmHg or diastolic blood pressure of > or = 90 mmHg].
+Blood pressure must be well-controlled (less than or equal to 140/90 mmHg at screening) with or without antihypertensive medication. Patients must have no history of hypertensive crisis or hypertensive encephalopathy;
+Uncontrolled hypertension (systolic blood pressure >150 millimeters of mercury [mmHg] or diastolic pressure >90 mmHg despite optimal medical management).
+Systolic blood pressure <90 mmHg.
+Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 150 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure must be re-assessed on two occasions that are separated by a minimum of 24 hours; the mean SBP/DBP values from each blood pressure assessment must be =< 150 systolic and 90 diastolic mmHg in order for a subject to be eligible for the study
+Uncontrolled hypertension, defined as systolic blood pressure >= 150 mmHg or a diastolic pressure >= 100 mmHg (the use of antihypertensive medications to achieve these goals is allowed)
+Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
+Uncontrolled hypertension, defined below:\r\n* Patients < 18 years old:\r\n** Diastolic Blood Pressure Within The Upper Limit Of Normal Defined as: A diastolic blood pressure (DBP) > the 95th percentile for age and gender despite optimal medical management\r\n* Patients >= 18 years old\r\n** Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medial management
+Poorly controlled systemic vascular hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg)
+Poorly controlled high blood pressure
+Uncontrolled hypertension with systolic blood pressure >160 mmHg
+Baseline arterial blood pressure (BP) >= 140/90 mmHg, despite pharmacologic treatment with antihypertensive agents; if the arterial BP measurements at screening are >= 140/90 mmHg in a patient not on pharmacologic treatment for hypertension (HTN), we will initiate pharmacologic therapy and reassess the parameters after 1 week; at that time, patient will be eligible for enrollment on the study if arterial BP is found < 140/90 mmHg on antihypertensive therapy
+Poorly controlled hypertension (defined as requiring changes in any hypertensive regimen within 1 week of study entry) or patients diagnosed with hypertension based on repeat blood pressure measurements of > 160/90 mmHg at screening
+Patients with uncontrolled hypertension (defined as sustained stage 2 hypertension, i.e., systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 100 mmHg) with or without medical therapy
+Subject has severe or uncontrolled systemic diseases including uncontrolled hypertension (blood pressure > 150/100 mmHg) or active bleeding diatheses.
+Patients who have uncontrolled hypertension (defined as sustained systolic blood pressure >= 160 mmHg or diastolic >= 100 mmHg)
+Uncontrolled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg)
+Poorly controlled hypertension (systolic blood pressure [SBP] >= 140 mmHg or diastolic blood pressure [DBP] >= 90 mmHg); the initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry
+Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
+Poorly controlled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 100 mmHg) on three or more readings in the past 12 months
+No uncontrolled hypertension (systolic blood pressure =< 160 millimeters of mercury [mmHg] or diastolic =< 100 mmHg); patients with hypertension must be adequately controlled with appropriate anti-hypertensive therapy or diet
+Blood pressure <=Grade 1 (hypertensive participants are permitted if their blood pressure is controlled to <=Grade 1 by hypertensive medications.
+Blood pressure ?Grade 1 (hypertensive participants are permitted if their blood pressure is controlled to ? Grade 1 by hypertensive medications and glycosylated hemoglobin is ?6.5%).
+Blood pressure (BP) ?140/90 millimeters of mercury (mmHg) at Screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1.
+Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg); anti-hypertensive therapy to achieve these parameters is allowed
+Stage 2 hypertension or greater (systolic blood pressure > 160 and/or diastolic blood pressure > 100)
+Significant cardiovascular disease precluding an exercise program, including recent (within 6 months) myocardial infarction or stroke, pulmonary edema, myocarditis, pericarditis, unstable angina, pulmonary embolism/deep venous thrombosis (PE/DVT), uncontrolled hypertension (systolic blood pressure [SBP] > 200; diastolic blood pressure [DBP] > 110), uncontrolled arrhythmia, heart failure; or
+Severe untreated resting arterial hypertension (> 200 mmHg systolic, > 120 mmHg diastolic) at the time of enrollment
+Resting blood pressure > 160/100
+Systolic pressure > 180 mmHg or diastolic pressure > 100 mmHg at the time of study enrollment
+Uncontrolled hypertension >= 2 times as noted in medical history (diastolic blood pressure > 100, systolic > 160) =< 90 days prior to registration
+Use of any other blood pressure lowering medication for treatment of hypertension, within 30 days of randomization
+Sitting systolic blood pressure > 90 mmHg
+Systolic blood pressure ?180 mmHg or diastolic blood pressure ?110 mmHg;
+Patients with a history of hypertension should be well controlled (blood pressure [BP] =< 140/90) on a regimen of antihypertensive therapy
+Systolic pressure > 180 mmHg or diastolic pressure > 100 mmHg at the time of study enrollment
+Systolic pressure > 180 mmHg or diastolic pressure > 100 mmHg at the time of study enrollment
+Uncontrolled hypertension (defined as blood pressure in adults > 150/95)\r\n* Patients on anti-hypertensive medications are eligible if blood pressure is controlled
+Uncontrolled hypertension (systolic blood pressure [BP] > 160 mmHg or diastolic BP > 100 mmHg), or as determined by the investigator during screening.
+Uncontrolled hypertension (systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg)
+Low resting systolic blood pressure: < 90 mmHg
+Uncontrolled arterial hypertension (systolic blood pressure > 200 mmHg, diastolic > 110 mmHg)
+Subjects who, at screening, have abnormal vital signs and/or physical exam, including a temperature >= 38.0 C, systolic blood pressure =< 90 or > 180 mmHg, pulse =< 60 or > 130 beats per minute, new rash, signs of infection
+High blood pressure
+High blood pressure
+Participants with a blood pressure >= 140/90 at the time of baseline testing
+Systolic/diastolic blood pressure (BP) greater than or equal to 160/100, or below 90/50 (one re-screen allowed)
+Uncontrolled hypertension (systolic blood pressure [SBP] greater than 180 or diastolic blood pressure [DBP] greater than 110)
+Uncontrolled or poorly controlled hypertension, defined as systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg, whether or not the subject is receiving anti-hypertensive treatment; subjects may be rescreened if the blood pressure is successfully and promptly controlled within 5 days using conventional anti-hypertensive therapy to achieve optimal blood pressure control (< 140/90 mmHg)
+Uncontrolled severe hypertension (systolic > 200mmHg or diastolic > 120 mmHg)
+Uncontrolled hypertension (systolic blood pressure; SBP greater than 180 or diastolic blood pressure; DBP greater than 110)
+Normotensive or controlled blood pressure (< 140/90) on a single anti-hypertensive medication
+Blood pressure > 140/90 at baseline by home monitoring
+Patients with hypertension not adequately controlled by medication (i.e. systolic blood pressure >= 150 and/or diastolic blood pressure >= 90 on at least two separate readings)
+Uncontrolled high blood pressure (BP) >= 160/100; persons can be re-screened after controlled
+Subjects who have diabetes or uncontrolled hypertension are not eligible; NOTE: for the purposes of this study, uncontrolled will be defined as diastolic pressure over 100 mmHg
+Patients who are hypotensive with a systolic blood pressure reading of < 110 mmHg at any time over the 3 days prior to study entry
+high blood pressure (defined as systolic blood pressure over 165 or diastolic blood pressure over 100),
+Poorly controlled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 1000 mmHg), with or without antihypertensives
+Fever of > 101 degrees Fahrenheit (F) or blood pressure (BP) > 180/95
+Have uncontrolled hypertension and resting blood pressure exceeding 140/80 mmHg
+Poorly controlled hypertension, with blood pressure at study entry > 160/100; the addition of anti-hypertensives to control blood pressure is allowed for eligibility determination
+Patient must not have poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg)\r\n* Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be < 140/90 mmHg in order for a subject to be eligible for the study prior to study enrollment)
+Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg)
+Uncontrolled hypertension (mmHg > 160 systolic or > 90 diastolic)
+Adequately controlled blood pressure with or without antihypertensive medications defined as blood pressure (BP) < 150/90 mmHg at screening
+Poorly controlled hypertension, with blood pressure at study entry > 160/100
+Systolic blood pressure < 90 prior to propranolol
+Uncontrolled hypertension, blood pressure (BP) > 150/100 mmHg; patients with elevated BP may enroll once BP is corrected
+Systolic blood pressure greater than 145 and diastolic blood pressure greater than 90
+Blood pressure between 90 and 150 mmHg systolic, inclusive, and not higher than 90 mmHg diastolic.
+Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ? 160 mmHg and/or Diastolic Blood Pressure (DBP) ? 100 mmHg, with or without anti-hypertensive medication.
+Intraocular pressure > 21 mmHg as measured by tonometry
+Blood pressure <= Grade 1 (hypertensive participants are permitted if their blood pressure is controlled to <= Grade 1 by hypotensive medications and glycosylated HbA1C <= 6.5%).
+Uncontrolled hypertension defined as systolic blood pressure ? 160 mmHg or diastolic blood pressure ? 100 mmHg, despite medical management
+Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ?150/90 mmHg at Screening and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1.